MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
32.53
-1.00
-2.98%
Closed 17:30 05/13 EDT
OPEN
33.47
PREV CLOSE
33.53
HIGH
33.82
LOW
32.38
VOLUME
1.36M
TURNOVER
25.10M
52 WEEK HIGH
52.34
52 WEEK LOW
23.95
MARKET CAP
5.18B
P/E (TTM)
-10.8949
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IONS last week (0505-0509)?
Weekly Report · 2d ago
IONIS PHARMACEUTICALS INC <IONS.O>: JEFFERIES RAISES TARGET PRICE TO $83 FROM $77
Reuters · 6d ago
Monday 5/5 Insider Buying Report: IONS, BDN
NASDAQ · 05/05 17:47
Weekly Report: what happened at IONS last week (0428-0502)?
Weekly Report · 05/05 09:10
How Will Vertex Pharmaceuticals Stock React To Its Upcoming Earnings?
NASDAQ · 05/05 03:21
Director Makes Bold Move with Major Stock Purchase in Ionis Pharmaceuticals
TipRanks · 05/03 02:07
Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates
Simply Wall St · 05/02 12:39
Tweedy, Browne Fund Q1 2025 Commentary
Seeking Alpha · 05/02 11:25
More
About IONS
More
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Recently
Symbol
Price
%Change

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.